Divis LaboratoriesNSE: DIVISLABBSE: 532488Healthcare · Pharmaceuticals

₹8,056.00221.00 (2.82%)

Mkt Cap: ₹2.13 L Cr.
P/E (TTM): 81.06
Open: ₹7,873.00
Day's Range: ₹7,870.50 – ₹8,090.00
52W Range: ₹5,636.50 – ₹7,938.00
Div Yield: 0.39%
EPS (TTM): ₹96.53
Book Value: ₹631.37

Divis Laboratories Financial Statements

Name: Divis Laboratories Financials — historical data
Creator: StockeZee

For Mar 2026, Divis Laboratories reported revenue of ₹10,560 crore and net profit of ₹2,568 crore. Return on equity stands at 16.50%. Profit & loss, balance sheet and cash flow across 9 reported years are below.

Updated 31 Jul 2026Source: NSE & BSE company filingsNifty 100 constituent

Latest year revenue: ₹10,560 Cr
EBITDA: ₹3,441 Cr
Operating margin: 32.59%
Profit after tax: ₹2,568 Cr
Net margin: 24.32%
EPS: ₹96.73
Latest year: Mar 2026
Years reported: 9

Divis Laboratories profit & loss

Reported annual performance for Divis Laboratories, oldest to newest. Figures in ₹ crore unless a row states otherwise.

Divis Laboratories annual profit and loss statement. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue from Operations	3,913	4,946	5,394	6,969	8,960	7,768	7,845	9,360	10,560
Sales Growth YoY %	—	26.41%	9.06%	29.2%	28.56%	-13.31%	1%	19.31%	12.82%
Other Income	113	156	190	63	114	345	339	352	507
Total Income	4,026	5,102	5,584	7,032	9,074	8,112	8,184	9,712	11,067
Cost of Goods Sold (COGS)	1,534	1,825	2,109	2,324	2,967	3,054	3,129	3,725	4,093
Cost of Materials Consumed	1,529	2,104	2,198	2,397	3,477	3,008	3,232	3,821	4,378
Purchases of Stock-in-Trade	2	26	16	5	14	22	6	0	0
Changes in Inventories	3	-305	-106	-79	-524	23	-109	-96	-285
Gross Profit	2,379	3,121	3,286	4,645	5,993	4,714	4,716	5,635	6,467
Gross Margin %	60.79%	63.1%	60.91%	66.65%	66.88%	60.69%	60.11%	60.2%	61.24%
Total Operating Expenses	1,117	1,249	1,464	1,785	2,111	2,346	2,511	2,667	3,026
Employee Benefit Expense	456	542	621	826	946	975	1,094	1,243	1,442
Other Expenses	661	707	843	960	1,165	1,371	1,417	1,424	1,584
EBITDA	1,262	1,872	1,822	2,860	3,882	2,368	2,205	2,968	3,441
OPM %	32.25%	37.84%	33.78%	41.04%	43.33%	30.48%	28.11%	31.71%	32.59%
Total Non-Operating Expenses	144	172	192	256	312	344	381	404	412
Depreciation & Amortisation	142	169	186	256	312	343	378	402	463
Finance Costs	1	4	6	1	1	1	3	2	23
Exceptional Items (Before Tax)	0	0	0	0	0	0	0	0	-74
Profit Before Tax (PBT)	1,231	1,855	1,819	2,666	3,684	2,369	2,163	2,916	3,388
Tax Expense	354	502	443	682	723	545	563	725	820
Current Tax	290	476	393	616	644	439	514	799	868
Deferred Tax	64	27	50	65	79	106	49	-74	-48
Effective Tax %	28.78%	27.08%	24.34%	25.57%	19.63%	23.02%	26.03%	24.86%	24.2%
Total Profit for Period	877	1,353	1,377	1,984	2,960	1,823	1,600	2,191	2,568
Net Profit (Owner's PAT)	877	1,353	1,377	1,984	2,960	1,823	1,600	2,191	2,568
Net Profit Margin %	22.41%	27.35%	25.52%	28.47%	33.04%	23.47%	20.4%	23.41%	24.32%
PAT Growth YoY %	—	54.24%	1.76%	44.15%	49.19%	-38.41%	-12.25%	36.94%	17.21%
Earnings Per Share (EPS)	₹33.04	₹50.96	₹51.85	₹74.75	₹111.52	₹68.69	₹60.27	₹82.53	₹96.73
Diluted Shares Outstanding (Cr.)	27	27	27	27	27	27	27	27	27
Other Comprehensive Income (Net of Tax)	10	-0	0	0	4	12	0	3	21
Expenses	2,795	3,247	3,765	4,366	5,390	5,744	6,021	6,796	7,679
Material Cost %	39.07%	42.53%	40.75%	34.4%	38.8%	38.73%	41.2%	40.82%	41.46%
Employee Cost %	11.66%	10.96%	11.51%	11.85%	10.56%	12.55%	13.95%	13.28%	13.66%
Other Cost %	16.89%	14.29%	15.62%	13.77%	13%	17.65%	18.06%	15.21%	15%
Interest Coverage (x)	841.52	486.55	268.19	2,993.51	4,463.04	3,021.85	609	1,283	129.48

Divis Laboratories revenue and profit trend

Reported annual revenue and net profit, oldest to newest. Two panels because the two measures live on different scales — one shared axis would distort both.

Divis Laboratories balance sheet

Assets, liabilities and shareholders' equity as reported, in Schedule III order. Figures in ₹ crore unless a row states otherwise.

Divis Laboratories annual balance sheet with assets, liabilities and equity. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Equity	6,957	7,310	9,295	11,728	12,767	13,571	14,969	16,761
Equity Share Capital	53	53	53	53	53	53	53	53
Reserves & Surplus	6,904	7,257	9,242	11,675	12,714	13,518	14,916	16,708
Total Equity	6,957	7,310	9,295	11,728	12,767	13,571	14,969	16,761
Non-Current Liabilities	234	299	367	451	571	621	511	1,229
Deferred Tax Liabilities	221	274	338	421	537	582	509	469
Non-Current Provisions	13	21	25	27	31	37	—	81
Other Non-Current Liabilities	—	—	—	—	—	—	—	218
Non-Current Financial Liabilities	—	4	4	3	3	2	2	461
Current Liabilities	847	927	1,112	1,196	1,101	1,278	1,452	2,043
Short-term Borrowings	106	34	0	—	—	—	2	—
Trade Payables	492	591	763	796	763	824	910	1,211
Current Financial Liabilities	661	731	845	859	806	925	1,046	1,673
Other Current Financial Liabilities	63	106	81	64	44	101	134	462
Other Current Liabilities	181	184	259	330	288	303	352	298
Current Provisions	1	2	3	4	5	7	54	60
Current Tax Liabilities	4	10	6	2	2	43	—	12
Total Liabilities	1,081	1,226	1,479	1,647	1,672	1,899	1,963	3,272
Total Non-Current Assets	3,388	3,856	4,599	5,023	5,127	5,795	6,851	8,937
Property, Plant & Equipment (PPE)	2,084	2,773	3,699	4,314	4,714	4,733	5,437	6,515
Capital Work-in-Progress	492	920	711	470	212	778	1,022	2,113
Intangible Assets	4	9	5	11	8	6	4	13
Non-Current Investments	547	0	0	72	77	82	65	69
Loans – Non-Current	34	35	55	—	—	—	—	—
Other Non-Current Assets	225	115	125	84	50	130	250	146
Non-Current Financial Assets	581	35	57	130	128	138	127	136
Net Fixed Assets	2,580	3,702	4,414	4,795	4,934	5,517	6,463	8,641
Total Current Assets	4,650	4,680	6,175	8,352	9,312	9,675	10,081	11,096
Inventories	1,772	1,864	2,145	2,829	3,000	3,184	3,236	3,954
Trade Receivables	1,163	1,413	1,677	2,424	1,793	2,156	2,731	2,984
Cash & Cash Equivalents	13	43	2,030	1,215	170	363	415	128
Current Investments	1,398	971	—	—	—	—	—	—
Loans – Current	0	0	—	—	—	—	—	—
Current Financial Assets	2,678	2,511	3,842	5,248	6,012	6,143	6,462	6,406
Other Current Assets	199	226	153	218	300	348	383	736
Other Current Financial Assets	1	4	9	5	6	7	16	8
Current Tax Assets	—	79	34	58	—	—	—	—
Net Working Capital	3,803	3,753	5,062	7,156	8,211	8,397	8,629	9,053
Additional Asset Fields	2	4	3	14	14	10	11	14
Def Tax Assets	2	4	3	14	14	10	11	14
Total Assets	8,038	8,536	10,774	13,375	14,439	15,470	16,932	20,033
Total Borrowings	106	34	0	—	—	—	2	—
Net Debt	93	-10	-2,030	—	—	—	-413	—
Debt to Equity (x)	0.02	0	0	—	—	—	0	—
Current Ratio (x)	5.49	5.05	5.55	6.99	8.46	7.57	6.94	5.43

Divis Laboratories cash flow statement

Cash generated and used across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.

Divis Laboratories annual cash flow statement across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Cash from Operating Activities	1,912	2,460	1,261	1,653	2,738
Profit Before Tax	3,684	2,369	2,163	2,916	3,388
Depreciation & Amortisation	312	343	378	402	463
Finance Costs	0	0	3	2	23
Working Capital Changes	-1,372	419	-607	-556	100
Tax Paid	-641	-473	-376	-824	-862
Net Cash from Investing Activities	-2,195	-2,708	-269	-804	-2,219
Purchase of PPE	-713	-473	-1,003	-1,438	-2,520
Sale of Fixed Assets	0	0	0	0	3
Interest Received	67	205	300	295	284
Net Cash from Financing Activities	-532	-797	-799	-799	-804
Proceeds from Borrowings	0	0	0	0	0
Repayment of Borrowings	-0	0	0	0	0
Interest Paid	-0	-0	-2	-2	-5
Dividend Paid	-531	-796	-796	-796	-797
Buyback / Redemption of Shares	0	0	0	0	0
Lease Liabilities Paid	-1	-0	-1	-1	-2
Net Change in Cash	-816	-1,045	193	50	-285
Effect of Foreign Exchange Changes	0	0	0	0	0
Free Cash Flow	1,199	1,987	258	215	218
CFO / PBT (x)	0.52	1.04	0.58	0.57	0.81

Divis Laboratories key ratios

Valuation, profitability, return, leverage and per-share measures computed from reported statements — not from adjusted or normalised earnings.

Divis Laboratories trades at a P/E of 81.06× against a sector median of 42.68× — a 90% premium. Sector comparisons can mislead for conglomerates with mixed business lines.

Divis Laboratories valuation, profitability, return and leverage ratios
Ratio	Category	Value
P/E (TTM)	Valuation	81.06
Forward P/E	Valuation	48.55
P/B	Valuation	12.42
PEG (TTM)	Valuation	5.6
EV / EBITDA (TTM)	Valuation	46.33
P/S (TTM)	Valuation	19.7
Operating margin	Profitability	32.6%
Net margin (TTM)	Profitability	24.36%
Return on equity	Return ratios	16.5%
Return on capital employed	Return ratios	22%
Return on assets	Return ratios	10.07%
Beta	Leverage & liquidity	0.62
EPS (TTM)	Per share	₹96.53
Book value	Per share	₹631.37
Revenue / share (TTM)	Per share	₹392.89
Cash flow / share	Per share	₹103.14
Dividend yield	Shareholder returns	0.39%
Dividend payout (TTM)	Shareholder returns	31.06%

How this is calculated

Statements are as filed with the exchanges. Consolidated figures are shown where reported. Figures are in rupees crore unless the table states otherwise. Ratios are computed from the same reported statements, not from adjusted or normalised earnings.

Index membership reflects the Nifty 100 as published by NSE Indices, effective 2026-03-30.

Divis Laboratories: frequently asked questions

What is Divis Laboratories's annual revenue?

Divis Laboratories reported revenue of ₹10,560 crore in Mar 2026, up 12.8% on the previous financial year.

Is Divis Laboratories profitable?

Divis Laboratories reported a net profit of ₹2,568 crore in Mar 2026, up 17.2% on the previous financial year.

What is Divis Laboratories's EPS?

Divis Laboratories reported earnings per share of ₹96.73 for Mar 2026.

What is Divis Laboratories's operating margin?

Divis Laboratories's operating margin for Mar 2026 was 32.59%.

What is Divis Laboratories's return on equity?

Divis Laboratories's return on equity stands at 16.50%. ROE measures profit generated per rupee of shareholder equity.

How many years of Divis Laboratories financials are shown?

9 reported financial years are tabulated on this page, the most recent being Mar 2026.

Are these figures consolidated or standalone?

Consolidated figures are shown wherever the company reports them, and standalone otherwise. The basis in use is labelled on the statement table.

More Divis Laboratories data

Compare financial statements with peers

Explore

Comparing financial statements across companies is more useful than reading one in isolation — the peer links above open the same view for Divis Laboratories’s closest listed competitors.

Disclaimer

The data, ratios and commentary about Divis Laboratories Ltd (DIVISLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.